J Pain Res. 2010 Nov 19;3:235-40. doi: 10.2147/JPR.S13894.

Pharmacokinetic profile of an intradeltoid diclofenac injection in obese Indian volunteers.

Journal of pain research

Dhaneshwar Shep, Ashwini Ojha, Sweta Patel, Manish Nivsarkar, Vijaya Jaiswal, Harish Padh

PMID: 21311716 PMCID: PMC3033031 DOI: 10.2147/JPR.S13894

Abstract

BACKGROUND: A new propylene glycol-free and reduced-volume formulation of diclofenac sodium 75 mg/mL designed for intradeltoid administration has been found to be bioequivalent to a reference formulation of diclofenac sodium 75 mg/3 mL given via the intragluteal route in normal healthy volunteers. Standard needles may not reach the gluteus maximus muscle in many cases, especially in the obese. The objective of this study was to determine the pharmacokinetic parameters of the new formulation and compare the bioavailability of intradeltoid diclofenac sodium 75 mg/mL with that of the intragluteal 75 mg/3 mL reference formulation in obese volunteers.

METHODS: A comparative, two-way, single-dose, bioavailability study was carried out in 10 obese (body mass index > 25) male Indian volunteers after a washout period of seven days. Blood samples were collected until six hours following drug administration and analyzed using a prevalidated high-pressure liquid chromatography method.

RESULTS: The mean maximum plasma concentration and time to reach maximum plasma concentration for the test formulation were 1.30 μg/mL and 0.50 hours, respectively, versus 0.93 μg/ mL and 1.08 hours for the reference formulation. The mean areas under the curve from 0 to last measurable time point (AUC(0-t)) for the test and reference formulations were 2.71 μg·h/mL and 2.73 μg·h/mL, respectively. The mean AUCs from 0 to infinity (AUC(0-∞)) for the test and reference formulations were 3.71 μg·h/mL and 3.75 μg·h/mL, respectively.

CONCLUSION: The results suggest that the test formulation of diclofenac sodium 75 mg/mL has an AUC(0-t) and AUC(0-∞) comparable with the reference intragluteal formulation of diclofenac sodium 75 mg/3 mL, but with an earlier time to reach maximum plasma concentration and a trend towards a higher maximum plasma concentration. This could be attributed to faster absorption from the deltoid region than from the gluteal region. The test formulation could be helpful in the management of pain in obese or overweight patients and those with dense subcutaneous fat in the gluteal area.

Keywords: bioavailability; diclofenac; intradeltoid; obese; pharmacokinetics

References

1. Eur J Radiol. 2006 Jun;58(3):480-4 - PubMed
2. Can J Anaesth. 2001 Jul-Aug;48(7):661-4 - PubMed
3. Vaccine. 2006 Feb 13;24(7):937-40 - PubMed
4. Expert Opin Pharmacother. 2009 Mar;10(4):517-22 - PubMed
5. Acta Anaesthesiol Scand. 2006 Mar;50(3):374-81 - PubMed
6. Clin Drug Investig. 2003;23(11):701-6 - PubMed
7. JAMA. 1997 Jun 4;277(21):1709-11 - PubMed
8. J Clin Pharmacol. 1983 Jan;23(1):48-55 - PubMed
9. Z Rheumatol. 1988 Jan-Feb;47(1):37-42 - PubMed
10. J Adv Nurs. 2007 Jun;58(6):552-6 - PubMed
11. Arch Med Res. 2001 Mar-Apr;32(2):148-54 - PubMed
12. Can Assoc Radiol J. 2007 Apr;58(2):72-5 - PubMed
13. Psychiatry (Edgmont). 2008 Sep;5(9):40-2 - PubMed
14. Clin Pharmacol Ther. 1975 Jan;17(1):44-7 - PubMed
15. J Med Assoc Thai. 2005 Jan;88(1):15-9 - PubMed
16. Clin Liver Dis. 2007 Aug;11(3):563-75, vi-vii - PubMed
17. BMJ. 2006 Mar 18;332(7542):637-8 - PubMed

Publication Types

• Journal Article